Pramipexole has been a widely used dopamine agonist for the last decade. Recently an extended release formulation of pramipexole has been introduced as both monotherapy for patients with early Parkinson's disease as well as for patients with more advanced disease, as an adjunct to L-DOPA. Along with the enhanced patient compliance seen with once a day dosing, there are other potential advantage...

Background. Parkinson's disease (PD) progressively affects dopaminergic neurotransmission and may affect retinal dopaminergic functions and structures. Objective. This 2-year randomized, open-label, parallel-group, flexible-dose study, NCT00144300, evaluated ophthalmologic safety profiles of immediate-release (IR) pramipexole and ropinirole in patients with early idiopathic PD with ≤6 months' p...

BACKGROUND Pramipexole, a new dopamine agonist, effectively treats early and advanced Parkinson disease and restless legs syndrome. OBJECTIVES To report the clinical features of and to investigate the predisposing factors and eventual outcomes in patients who developed peripheral edema (PE) following treatment with pramipexole. DESIGN Retrospective case series in a tertiary referral center....

Pramipexole has been shown to possess neuroprotective properties in vitro that are partly independent of its dopaminergic agonism. The site of neuroprotective action is still unknown. Using [(3)H]pramipexole, we show that the drug enters and accumulates in cells and mitochondria. Detoxification of reactive oxygen species (ROS) by pramipexole is shown in vitro and in vivo by evaluating mitochond...

background: the ketogenic diet (kd), high in fat and low in carbohydrate and protein, provides sufficient protein but insufficient carbohydrates for all the metabolic needs of the body. kd has been known as a therapeutic manner intractable epilepsy. in recent years, the effectiveness of kd drew attention to the treatment of some other disorders such as parkinson’s disease (pd). this study has e...

We report a fatal intoxication in a 59-year-old woman who had uremia undergoing hemodialysis, and then took amantadine and pramipexole for Parkinsonian tremor. Toxic manifestation includes myoclonus, ataxia, confusion and sudden death. This report highlights the fact that using amantadine and pramipexole may be fatal in patients with uremia even undergoing hemodialysis.

OBJECTIVE To compare the efficacy of the three nonergot dopamine-receptor agonists (DAs) pramipexole, ropinirole, and rotigotine for the treatment of early and advanced Parkinson's disease (PD). MATERIALS AND METHODS Bayesian network meta-analyses were performed separately for early and advanced PD, and at time points 11-16 and 24-28 weeks. Outcomes for early PD included improvement on the Un...

BACKGROUND Treatment of Parkinson disease commonly includes levodopa and dopamine agonists; however, the interaction of these 2 drugs is poorly understood. OBJECTIVE To examine the effects of a dopamine agonist on the motor response to levodopa. DESIGN Double-blind, randomized, placebo-controlled, crossover clinical trial. SETTING Ambulatory academic referral center. Patients Thirteen pat...

Depression occurs in approximately 45% of all patients with Parkinson's disease (PD), does not correlate with the stage of motor deficits, reduces quality of life independently of motor symptoms and appears to be underrated and undertreated. Anxiety and depression are the risk factors for the development of PD and may be present many years before the appearance of motor symptoms. Studies using ...

AIMS AND METHOD To review the evidence for this use of pramipexole in the treatment of unipolar and bipolar depression, a literature search on Embase and Medline was conducted in December 2003. The search was updated in July 2004. The reference sections of retrieved papers were searched for further relevant references. RESULTS There are limited data on the clinical use of pramipexole in affecti...